Oral Micronized Progesterone: Why It Is Not Injected and How to Take It Correctly

Self-Injection Does Not Apply to This Drug

Oral micronized progesterone is formulated as a soft gelatin capsule taken by mouth. There is no injectable version of micronized progesterone marketed under the Prometrium brand, and no self-injection technique exists for this medication. Patients searching for "progesterone injection" may be thinking of intramuscular progesterone in oil, which is a different formulation used primarily in assisted reproduction protocols.

Why the Confusion Exists

Injectable progesterone in oil (typically 50 mg/mL in sesame or castor oil) is prescribed for luteal-phase support during IVF cycles and for select cases of threatened miscarriage. That product requires intramuscular injection into the gluteal muscle. Oral micronized progesterone replaced the need for those injections in many HRT scenarios after the PEPI Trial demonstrated that a capsule taken by mouth provided equivalent endometrial protection [1].

When Injectable Progesterone Is Still Used

Intramuscular progesterone in oil remains standard in fresh embryo transfer cycles, where higher serum concentrations are needed rapidly. The American Society for Reproductive Medicine (ASRM) notes that vaginal and intramuscular routes achieve comparable live-birth rates in most IVF protocols [2]. For menopause-related HRT, oral micronized progesterone is the preferred route. If your provider has prescribed an injectable form of progesterone, the administration instructions will differ entirely from what is described here.

How to Take Oral Micronized Progesterone Correctly

The correct "technique" for this drug is oral administration, and small details in timing and food intake affect how well it works. The FDA-approved labeling specifies taking Prometrium at bedtime with food. This is not a suggestion.

Why Bedtime Dosing Matters

Progesterone is metabolized in the liver into allopregnanolone, a neuroactive steroid that binds GABA-A receptors and produces sedation. A pharmacokinetic study published in Fertility and Sterility found that peak serum progesterone levels occurred approximately 3 hours after oral dosing, coinciding with maximum drowsiness [3]. Taking the capsule at bedtime turns this side effect into a benefit for sleep quality.

Why Food Is Required

Micronized progesterone is suspended in peanut oil inside the capsule specifically because progesterone is lipophilic and dissolves poorly in water. A study by Simon et al. Demonstrated that taking the capsule with food increased area-under-the-curve (AUC) bioavailability by approximately 25% compared to fasting [3]. A small meal or snack containing some dietary fat is sufficient.

Step-by-Step Oral Administration

1. Take the capsule at the same time each evening, ideally within 30 minutes of your last meal or a bedtime snack.
2. Swallow the capsule whole with water. Do not open, crush, or chew it.
3. If you miss a dose by more than a few hours, skip it and resume the next evening. Do not double up.
4. Store capsules at room temperature (20 to 25 °C) away from moisture.

How Oral Micronized Progesterone Works

Micronized progesterone is bioidentical, meaning its molecular structure is identical to the progesterone produced by the human corpus luteum (C₂₁H₃₀O₂). The micronization process grinds progesterone crystals into particles smaller than 10 micrometers, which dramatically increases surface area and allows adequate absorption from the gastrointestinal tract.

Receptor-Level Mechanism

After absorption, progesterone binds to nuclear progesterone receptors (PR-A and PR-B) in target tissues. In the endometrium, this binding opposes estrogen-driven proliferation by downregulating estrogen receptors and activating secretory differentiation of glandular epithelium [4]. Without progesterone opposition, unopposed estrogen therapy increases the risk of endometrial hyperplasia. The PEPI Trial found that after 3 years, women on unopposed conjugated equine estrogen (CEE) had a 34% rate of adenomatous or atypical hyperplasia, while women receiving CEE plus oral micronized progesterone (200 mg for 12 days per cycle) had a rate no different from placebo [1].

Metabolic Pathway

Oral micronized progesterone undergoes significant first-pass hepatic metabolism. The primary metabolites are pregnanediols and pregnanolones, including the neuroactive 5α-pregnanolone (allopregnanolone). This first-pass effect means oral bioavailability is low compared to vaginal or intramuscular routes, but the metabolite profile contributes to beneficial effects on sleep and anxiety that parenteral routes do not provide [5].

Lipid Advantage Over Synthetic Progestins

One of the strongest arguments for micronized progesterone over medroxyprogesterone acetate (MPA) comes from lipid data. The PEPI Trial showed that MPA partially blunted the HDL-raising effect of estrogen, while micronized progesterone preserved the full estrogen-mediated HDL increase of approximately 4 to 6 mg/dL [1]. The 2022 North American Menopause Society (NAMS) position statement specifically notes micronized progesterone as a preferred option when lipid-neutrality is a clinical priority [6].

Dosing Protocols: Cyclic vs. Continuous

Prescribers choose between two standard regimens based on where a patient is in the menopause transition and whether withdrawal bleeding is acceptable.

Cyclic Dosing

The regimen validated in the PEPI Trial was 200 mg nightly for 12 consecutive days each calendar month, paired with continuous daily estrogen [1]. This produces a predictable withdrawal bleed 2 to 3 days after the last progesterone dose. It is preferred in perimenopausal women and in early postmenopausal women who tolerate monthly bleeding.

Continuous-Combined Dosing

For women who are at least 12 months past their final menstrual period and want to avoid bleeding, 100 mg nightly every day is the standard continuous regimen. A randomized trial by Luciano et al. Found that continuous 100 mg micronized progesterone combined with daily estradiol achieved amenorrhea in 80% of women by month 6 [7]. Breakthrough spotting in the first 3 months is common and does not indicate treatment failure.

Off-Label Vaginal Administration

Some clinicians prescribe the oral capsule for vaginal insertion, which bypasses first-pass metabolism, reduces sedation, and delivers higher local endometrial concentrations. A pharmacokinetic comparison by Levine and Watson showed vaginal administration produced endometrial progesterone levels approximately 10-fold higher than oral dosing at equivalent serum concentrations [8]. The Endocrine Society has acknowledged this route in clinical practice guidelines, though it remains off-label for the Prometrium capsule.

Safety Profile and Contraindications

Oral micronized progesterone has a narrower side-effect profile than synthetic progestins, but it is not without risks.

Common Side Effects

Drowsiness and dizziness affect roughly 15 to 20% of patients in the first month and typically attenuate. Breast tenderness and bloating occur at rates similar to MPA. A pooled safety analysis from the FDA-approved labeling lists headache (13%), abdominal pain (10%), and nausea (8%) as the most frequently reported adverse events [9].

Peanut Allergy

Prometrium capsules contain peanut oil. Patients with confirmed peanut allergy should not use brand-name Prometrium. Some generic micronized progesterone capsules use alternative oil vehicles (sunflower oil, for example). Confirm the inactive ingredient list before prescribing or dispensing to any patient with a peanut or tree-nut allergy.

Breast Cancer Considerations

The French E3N cohort study (N=80,377) followed women for a mean of 8.1 years and found that estrogen combined with micronized progesterone showed no statistically significant increase in breast cancer risk (RR 1.00; 95% CI 0.83 to 1.22), while estrogen plus synthetic progestins showed a significantly elevated risk (RR 1.69) [10]. This finding does not mean micronized progesterone is categorically "safe" for breast tissue, but it does distinguish it from MPA in observational data.

Contraindications

FDA-listed contraindications include known or suspected breast cancer, active deep vein thrombosis or pulmonary embolism, active arterial thromboembolic disease, known hepatic impairment, and undiagnosed abnormal genital bleeding.

Monitoring While on Oral Micronized Progesterone

No routine serum progesterone monitoring is needed for HRT-dose micronized progesterone. The clinical endpoint is endometrial protection, assessed by the absence of abnormal uterine bleeding.

When to Investigate

Unscheduled bleeding after 6 months of continuous-combined therapy or heavy bleeding on cyclic therapy warrants transvaginal ultrasound to measure endometrial thickness [11]. An endometrial thickness of 4 mm or less in a postmenopausal woman has a negative predictive value exceeding 99% for endometrial cancer. Endometrial biopsy is indicated if the stripe exceeds 4 mm or if bleeding persists despite a thin stripe.

Periodic Reassessment

The 2022 NAMS position statement recommends that HRT (including the progesterone component) be reassessed annually with an individualized risk-benefit discussion [6]. There is no mandatory stop date, but the rationale for continued use should be documented at each visit.

Oral Micronized Progesterone vs. Other Progesterone Routes

Patients sometimes ask whether they should switch from oral to vaginal, transdermal, or injectable progesterone. The answer depends on clinical goals.

Oral vs. Vaginal

Oral delivery produces higher systemic metabolite levels (more sedation, potential sleep benefit). Vaginal delivery produces higher endometrial tissue levels with fewer systemic side effects [8]. For women who experience intolerable drowsiness or dizziness on oral dosing, vaginal insertion of the same capsule is a practical alternative.

Oral vs. Transdermal

Transdermal progesterone creams are available over the counter but deliver unreliable and often sub-therapeutic serum levels. A systematic review by Stanczyk et al. Found that most OTC progesterone creams failed to raise serum progesterone above 3 ng/mL, insufficient for endometrial protection [12]. Oral micronized progesterone is the evidence-based choice when endometrial opposition is the clinical goal.

Oral vs. Intramuscular

Intramuscular progesterone in oil achieves higher and more consistent serum levels but requires painful gluteal injections, risks injection-site reactions, and is inconvenient for long-term HRT. Its use is appropriate in fertility medicine, not for routine menopause management.

Practical Tips for Patients

A few non-obvious points improve adherence and outcomes with this medication.

Short list of things that matter: take it at the exact same time each night. Pair it with a fat-containing snack, even a tablespoon of peanut butter or a few cheese crackers. Expect drowsiness in the first two weeks. Do not drive or operate machinery within 2 hours of dosing until you know how the drug affects you.

If you are using the capsule vaginally (as directed by your provider), insert it at bedtime while lying down. Some capsule shell residue may be expelled the following morning. This is normal and does not indicate failed absorption. The progesterone itself absorbs through the vaginal mucosa within 4 to 6 hours.

Report any persistent unscheduled bleeding beyond the first 3 months of continuous therapy. A single episode of spotting is rarely significant, but a pattern warrants evaluation.